Safety and Efficacy of Subcutaneous-Only Granulocyte-Macrophage Colony-Stimulating Factor for Collateral Growth Promotion in Patients With Coronary Artery Disease  by Zbinden, Stephan et al.
FS
G
F
P
S
C
B
A
a
a
b
o
a
a
m
(
g
C
a
S
1
2
Journal of the American College of Cardiology Vol. 46, No. 9, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
POCUS ISSUE: CARDIAC REGENERATION
afety and Efficacy of Subcutaneous-Only
ranulocyte-Macrophage Colony-Stimulating
actor for Collateral Growth Promotion in
atients With Coronary Artery Disease
tephan Zbinden, MD, Rainer Zbinden, MD, Pascal Meier, MD, Stephan Windecker, MD,
hristian Seiler, MD, FACC, FESC
ern, Switzerland
OBJECTIVES This study was designed to investigate the safety and efficacy of a short-term subcutaneous-
only granulocyte-macrophage colony-stimulating factor (GM-CSF) protocol for coronary
collateral growth promotion.
BACKGROUND The safety and efficacy of an exclusively systemic application of GM-CSF in patients with
coronary artery disease (CAD) and collateral artery promotion has not been studied so far.
METHODS In 14 men (age 61  11 years) with chronic stable CAD, the effect of GM-CSF
(molgramostim) on quantitatively assessed collateral flow was tested in a randomized,
double-blind, placebo-controlled fashion. The study protocol consisted of an invasive
collateral flow index (CFI) measurement in a stenotic as well as a normal coronary artery
before and after a two-week period with subcutaneous GM-CSF (10 g/kg; n  7) or
placebo (n 7). Collateral flow index was determined by simultaneous measurement of mean
aortic, distal coronary occlusive, and central venous pressure.
RESULTS Collateral flow index in all vessels changed from 0.116  0.05 to 0.159  0.07 in the
GM-CSF group (p  0.028) and from 0.166  0.06 to 0.166  0.04 in the placebo group
(p  NS). The treatment-induced difference in CFI was 0.042  0.05 in the GM-CSF
group and 0.001  0.04 in the placebo group (p  0.035). Among 11 determined
cytokines, chemokines, and their monocytic receptor concentrations, the treatment-induced
change in CFI was predicted by the respective change in tumor necrosis factor-alpha
concentration. Two of seven patients in the GM-CSF group and none in the placebo group
suffered an acute coronary syndrome during the treatment period.
CONCLUSIONS A subcutaneous-only, short-term protocol of GM-CSF is effective in promoting coronary
collateral artery growth among patients with CAD. However, the drug’s safety regarding the
occurrence of acute coronary syndrome is questionable. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.0681636–42) © 2005 by the American College of Cardiology Foundation
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mrevascularization strategy alternative to bypass surgery or
ngioplasty is warranted, both to control symptoms and to
lter the course of severe coronary artery disease (CAD),
ecause the traditional approaches are not suitable in 1 out
See page 1649
f 5 to 3 patients. The promotion of preformed collateral
rteries to a myocardial territory jeopardized by a blocked
rtery is such an option. Experimentally, there have been
any candidates with angiogenic or arteriogenic properties
1), but in only one controlled clinical investigation using
ranulocyte-macrophage colony-stimulating factor (GM-
SF) has the promotion of large, conductive collateral
rteries (arteriogenesis) been documented to be attainable
From the Department of Cardiology, University Hospital, Bern, Switzerland.
upported by a grant from the Swiss National Science Foundation, #3200BO-
00065/1. The first two authors contributed equally to this work.(
Manuscript received October 20, 2004; revised manuscript received January 19,
005, accepted January 25, 2005.2). Conversely, inducing the growth of capillary-like col-
ateral vessels (angiogenesis) in patients with CAD has not
nfluenced myocardial perfusion (3,4). With pro-angiogenic
nd -arteriogenic substances, the risk of advancing athero-
clerosis while promoting vascular detours has been criti-
ized (5). During arteriogenesis, monocytes seem to prefer-
ntially adhere to the endothelium of vessels subject to
igh-velocity blood flow owing to a pressure gradient
etween a collateral supplying artery and a blocked vascular
erritory (i.e., homing). In this context, it is probably not
ecessary to deliver growth factors for monocyte stimulation
ocally, as performed in our recent study (2), but they can be
iven systemically.
On the basis of these considerations, the goal of the
resent controlled study was to investigate the safety and
fficacy of a short-term subcutaneous-only GM-CSF pro-
ocol for coronary collateral growth promotion. The follow-
ng hypotheses were tested: GM-CSF is safe and it aug-
ents directly obtained coronary collateral flow index (CFI)
Fig. 1).
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atients. Fourteen patients (age 61 11 years, all men) with
hronic stable one- (n  4) or two-vessel (n  10) CAD
ligible for percutaneous coronary intervention (PCI) were
ncluded in the study. Patients were prospectively selected on
he basis of the following criteria: 1) no previous transmural
nfarction in the myocardial area assessed for coronary collat-
rals, 2) normal left ventricular ejection fraction, 3) no conges-
ive heart failure, 4) no baseline electrocardiogram (ECG)
T-segment abnormalities, 5) no signs of inflammatory illness,
) absence of overt neoplastic disease, and 7) no diabetic
Abbreviations and Acronyms
CAD  coronary artery disease
CFI  collateral flow index
CVP  central venous pressure
ECG  electrocardiogram
GM-CSF  granulocyte-macrophage colony-stimulating
factor
Pao  mean aortic pressure
Poccl  mean coronary artery occlusive pressure
PCI  percutaneous coronary intervention
TNF  tumor necrosis factor
igure 1. Determination of collateral flow index (CFI) in a patient rece
ntracoronary (i.c.) electrocardiogram (ECG) lead recordings are shown in
reatment, there are ST-segment elevations on the i.c. ECG lead, indicatin
ndex is calculated by dividing distal mean coronary occlusive pressure (Poccl, mm
Pao, mm Hg) minus CVP.etinopathy. Patients were randomly assigned to a two-week,
ouble-blind protocol of subcutaneous GM-CSF (mol-
ramostim; Novartis, Basel, Switzerland; n  7) or placebo (n
7). Collaterals were assessed invasively during balloon
cclusion in a stenotic and a normal coronary artery (1 to 2 atm
alloon inflation) at baseline before and immediately after the
reatment period (i.e., before PCI). The study was terminated
arly because of two serious adverse cardiac events in the
reatment arm of the study.
This investigation was approved by the institutional
thics committee, and the patients gave written informed
onsent to participate in the study.
ardiac catheterization and coronary angiography. Pa-
ients underwent left heart catheterization from the right
emoral approach. Aortic pressure was measured using a 6-F
CI guiding catheter. Central venous pressure was obtained
ia the right femoral vein. Left ventricular end-diastolic
ressure was determined before PCI. Biplane left ventricu-
ography was performed followed by biplane coronary an-
iography. Coronary artery stenoses were determined quan-
itatively as percent diameter narrowing.
oronary collateral assessment. Coronary collaterals were
ssessed dichotomously according to the presence or ab-
ence of ECG signs of myocardial ischemia at the end of a
placebo before (left) and after treatment (right). Surface (III, avF) and
upper part of the panels. After 1 min of vessel occlusion before and after
nary collaterals insufficient to prevent myocardial ischemia. Collateral flowiving
the
g coro
Hg) minus central venous pressure (CVP, mmHg) by mean aortic pressure
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yocardial ischemia was defined as ST-segment changes
0.1 mV (Fig. 1).
rimary end point of the study. Coronary collateral flow
elative to normal antegrade flow through the non-occluded
essel (CFI) was determined using coronary pressure measure-
ents. A 0.014-in pressure monitoring angioplasty guidewire
Pressure Wave, Endosonics, Mountain View, California) was
et at zero, calibrated, advanced through the guiding catheter,
nd positioned in the distal part of the vessel of interest.
ollateral flow index was determined by simultaneous mea-
urement of mean aortic pressure (Pao, mm Hg), the distal
oronary artery pressure during balloon occlusion (Poccl, mm
g), and the central venous pressure (CVP, mm Hg) (Fig. 1).
ollateral flow index was calculated as (Poccl  CVP) divided
y (Pao  CVP). The accuracy of pressure in comparison to
oppler-derived CFI measurements and to ECG signs of
yocardial ischemia during occlusion has been documented
reviously (6).
etermination of progenitor cells, cytokines, chemo-
ines, and their receptors. PROGENITOR CELLS. For
uantitation of the CD34 messenger ribonucleic acid, a
eal-time quantitative polymerase chain reaction assay based
n a specific set of primers and probe (Assays-on-Demand,
ene Expression Products) supplied by Applied Biosystems
Rotkreuz, Switzerland) was used.
YTOKINES AND CHEMOKINES. Concentrations of GM-
SF, monocyte chemoattractant protein-1 (MCP-1), basic
broblast growth factor, and vascular endothelial growth
actor were determined as immunoreactivity using a quan-
itative sandwich enzyme immunoassay technique (Quan-
ikine, R and D Systems, Minneapolis, Minnesota). Con-
entrations of tumor necrosis factor (TNF)-alpha and
nterleukin (IL)-6 were determined by immunometric as-
ays (Immulite, DPC, Los Angeles, California) according to
he manufacturer’s guidelines. Fractalkine concentration
as assessed using enzyme-linked immunosorbent assay
ith mouse anti-human Fractalkine capture antibody and
iotinylated mouse anti-human Fractalkine detection antibod-
es (DuoSet; R and D Systems, Minneapolis, Minnesota).
YTOKINE AND CHEMOKINE RECEPTORS. Cytokine and
hemokine monocyte receptor concentrations (TNF-alpha
eceptor, TNFR1; MCP-1 receptor, CCR2; Fractalkine
eceptor, CXCR1) were determined by fluorescent-
ctivated cell sorting analysis on CD14mononuclear cells.
tatistical analysis. Between-group comparisons of con-
inuous clinical, hemodynamic, angiographic, blood analysis
nd collateral flow data were performed by a Mann-
hitney test. A chi-square test was used for comparison of
ategorical variables among the two study groups. Intrain-
ividual comparison of baseline versus follow-up data was
erformed using Wilcoxon signed-rank test. Linear regres-
ion analysis was performed to assess an association between
reatment-induced alterations of CD34 cells, cytokines,
hemokines, their receptors, and CFI changes. Parameters
C
ignificantly related to CFI changes in this univariate regres-
ion analysis were entered in a multivariate stepwise regression
nalysis model for the determination of factors independently
redicting CFI. Mean values  SD are given.
ESULTS
atient characteristics and clinical data at baseline.
here were no statistically significant differences between
he two groups regarding age of the patients, gender, body
ass index, heart rate, or severity and duration of angina
ectoris. There were no statistical differences in the fre-
uency of cardiovascular risk factors and the use of acetyl-
alicylic acid, vasoactive drugs, statins, or diuretics (Table 1).
emodynamic, coronary structure, function, and collat-
ral data at baseline. Mean blood pressure during vessel
cclusion, left ventricular ejection fraction, end-diastolic
ressure, central venous pressure, pressure during coronary
cclusion in the stenotic and the normal vessel were similar
etween the study groups at baseline (Table 2). There were
o differences among the groups in the number of vessels
ith relevant stenotic lesions, in the total number of
emodynamically relevant stenoses, in the vessel selected for
CI, in the angiographic severity of the treated stenosis, and
n the hemodynamic degree of obstruction (fractional flow
eserve) of the stenotic or normal vessel.
Qualitative and quantitative variables for the assessment
f the collateral circulation were similar among the groups
Table 2).
ide effects. Two patients in the GM-CSF group and
one in the placebo group suffered an acute coronary
yndrome with proximal occlusion of the left anterior
escending coronary artery (at day 12 of the treatment
able 1. Patient Characteristics and Clinical Data at Baseline
GM-CSF
(n  7)
Placebo
(n  7) p
ge (yrs) 65  9 57  13 0.22
ale gender (%) 7 (100) 7 (100) —
ody mass index (kg/m2) 29  4 27  6 0.55
eart rate (beats/min) 64  9 73  22 0.32
ngina pectoris CCS class 1.6  1.4 1.4  0.8 0.75
uration of angina pectoris
(months)
19  27 8  14 0.40
moking (%) 4 (57) 3 (43) 0.78
ypercholesterolemia (%) 6 (86) 4 (57) 0.46
ypertension (%) 3 (43) 3 (43) 0.83
besity (%) 6 (86) 4 (57) 0.18
amily history for CAD (%) 6 (86) 3 (43) 0.20
iabetes mellitus (%) 0 (0) 1 (14) 0.27
cetylsalicylic acid (%) 6 (86) 7 (100) 0.48
eta-blockers (%) 7 (100) 4 (57) 0.18
alcium antagonists (%) 1 (14) 0 (0) 0.33
itrates (%) 1 (14) 2 (29) 0.44
ngiotensin-converting enzyme
inhibitor (%)
2 (29) 1 (14) 0.60
tatin (%) 7 (100) 3 (43) 0.07
iuretica (%) 2 (29) 1 (14) 0.60AD coronary artery disease; CCS Canadian Cardiovascular Society; GM-CSF
granulocyte macrophage-colony stimulating factor.
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November 1, 2005:1636–42 Systemic GM-CSF and Collateralsrotocol) and proximal occlusion of the right coronary
rtery (at day 9 of the treatment protocol) (Fig. 2). The
essel could be successfully recanalized in both individ-
als. Maximum creatine kinase levels following the event
ere 64 and 622 U/l. Patients of the GM-CSF group
omplained about any side effect in 6 of 7 instances and
hose in the placebo group did so in 2 of 7 cases (p 
.05). Low fever temperatures occurred in 3 of 7 patients
n the GM-CSF group and in none in the placebo group
p  NS). Skin rashes during treatment appeared in 7 of
cases in the GM-CSF group and in 2 of 7 placebo cases
p  0.01).
reatment-induced laboratory parameter and collateral
ow changes. Total leucocyte count, neutrophils, eosino-
hils, and monocytes increased significantly in the GM-
SF group, whereas they remained statistically unchanged
Table 2. Hemodynamic, Coronary Structural,
Hemodynamic data
Mean blood pressure during occlusion (Pao, mm H
Left ventricular ejection fraction (%)
Left ventricular end-diastolic pressure (mm Hg)
Central venous pressure during occlusion (mm Hg
Coronary occlusive pressure, path. (Poccl)
Coronary occlusive pressure, norm. (Poccl)
Coronary structure and function
Number of vessels diseased
Number of stenoses 50% in diameter
Vessel (PCI): LAD/LCX/RCA
Percent diameter stenosis of treated lesion
Fractional flow reserve, stenotic vessel
Fractional flow reserve, normal vessel
Collateral assessment
Angina pectoris during occlusion (%)
ECG ST-segment changes 1 mm during occlus
Collateral flow index, path. (no unit)
Collateral flow index, norm. (no unit)
GM-CSF  granulocyte-macrophage colony-stimulating fac
circumflex coronary artery; norm.  normal artery; path. 
intervention; RCA  right coronary artery.
igure 2. Angiograms showing the right coronary artery of a patient rece
efore treatment (day 0), multiple proximal stenoses with hazy appearance
o the hospital with an acute coronary syndrome; the extensively calcified righ
uccessfully recanalized (right panel).n the placebo group (Table 3). CD34 cells showed a
rend to decrease in the treatment group and to increase in
he placebo group. Total and high-density lipoprotein
holesterol decreased significantly in the GM-CSF group,
hereas they remained stable in the placebo group. Among
he growth factor, cytokine, and chemokine concentra-
ions obtained, the following increased significantly dur-
ng follow-up in the treatment but not in the placebo
roup: GM-CSF, TNF-alpha, and MCP-1 (Table 3).
he concentrations of basic fibroblast growth factor,
ascular endothelial growth factor, and fractalkine did
ot alter relevantly either in the treatment or the placebo
roup. TNFR1 and CXCR1 monocyte receptor concentra-
ion was significantly up- and down-regulated, respectively
n the GM-CSF but not in the placebo group (Table 4).
he CCR2 receptor concentration remained statistically
tional, and Collateral Data at Baseline
GM-CSF
(n  7)
Placebo
(n  7) p
91  10 93  24 0.85
61  11 66  6 0.29
9  2 11  8 0.55
4  1 5  4 0.78
18  6 22  7 0.33
21  11 18  5 0.60
2.1  0.6 1.7  0.8 0.28
2.4  1.3 2.1  1.8 0.78
3/2/2 2/2/3 0.69
62  22 65  32 0.82
0.68  0.19 0.72  0.11 0.63
0.89  0.14 0.94  0.02 0.41
7 (100) 6 (86) 0.75
) 6 (86) 5 (71) 0.45
0.091  0.050 0.173  0.080 0.38
0.142  0.089 0.163  0.058 0.54
AD  left anterior descending coronary artery; LCX  left
ologic, i.e., stenotic artery; PCI  percutaneous coronary
granulocyte-macrophage colony-stimulating factor. On the image taken
isible (1). At day 9 of the treatment protocol, the patient was admittedFunc
g)
)
ion (%
tor; Living
are vt coronary artery was proximally occluded (middle panel), and could be
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Systemic GM-CSF and Collaterals November 1, 2005:1636–42nchanged. Electrocardiographic signs of myocardial isch-
mia disappeared more often in the GM-CSF versus the
lacebo group (Table 4). Collateral flow index of all vessels
ncreased significantly in the GM-CSF group, and it re-
ained unaltered in the placebo group (Table 4, Fig. 3). A
imilar pattern was observed in the vascular subgroups of
tenotic and normal coronary arteries. Among 11 variables
initial CFI, treatment-induced change [] of neutrophils,
osinophils, monocytes, cholesterol, high-density lipopro-
ein, GM-CSF, TNF-alpha, MCP-1, TNFR1, CXCR1)
able 3. Treatment-Induced Laboratory Parameter Changes
GM-C
Before
Treatment
eucocytes (total; 109/l) 7.9  1.7 3
Neutrophils (109/l) 5.04  1.00 2
Eosinophils (109/l) 0.15  0.10
Basophils (109/l) 0.03  0.03 0
Monocytes (109/l) 0.64  0.16 1
Lymphocytes (109/l) 2.06  0.72 1
D34 cells (% expression of CD34 cell line) 0.051  0.04 0.0
otal serum cholesterol (mmol/l) 4.0  1.0
DL cholesterol (mmol/l) 1.2  0.3
M-CSF (pg/ml) 3.0  0.0 1
NF-alpha (pg/ml) 2.7  0.9 1
CP-1 (pg/ml) 415  233 6
FGF (pg/ml) 9.7  6.9 1
EGF (pg/ml) 16.6  15.9 4
nterleukin-6 (pg/ml) 2.0  0.0 1
raktalkine (pg/ml) 1,954  742 2,8
p  0.02 versus GM-CSF.
bFGF  basic fibroblast growth factor; GM-CSF  granulocyte-macrophag
hemoattractant protein-1; TNF  tumor necrosis factor; VEGF  vascular endoth
able 4. Treatment-Induced Receptor Expression and Collateral
G
Before
Treatment
onocyte receptor expression
TNFR1 (TNF-alpha receptor; relative fluorescence) 0.6  0.4
CCR2 (MCP-1 receptor) 0.2  0.1
CXCR1 (Fraktalkine receptor) 7.4  2.6
ollateral flow data: all vessels
ECG ST-segment changes 1 mm during
occlusion (%)
12 (86)
Collateral flow index (no unit) 0.116  0.05
Collateral flow index change after-before 0.04
ollateral flow data: stenotic vessels
ECG ST-segment changes 1 mm during
occlusion (%)
6 (86)
Collateral flow index (no unit) 0.091  0.05
Collateral flow index change after-before 0.04
ollateral flow data: normal vessels
ECG ST-segment changes 1 mm during
occlusion (%)
6 (86)
Collateral flow index (no unit) 0.142  0.08
Collateral flow index change after-before 0.04p  0.02 versus GM-CSF.
ECG  electrocardiogram; other abbreviations as in Table 3.xamined by univariate linear regression analysis for their
ssociation to CFI change, TNF-alpha was the only factor
ndependently predictive of CFI (Fig. 4). Tumor necrosis
actor-alpha change was, itself, related to TNFR1 change:
TNF-alpha  0.053  6.447TNFR1; r2  0.61, p 
.0001.
ISCUSSION
he present study shows that a purely systemic application
f GM-CSF is effective in promoting coronary collateral
n  7) Placebo (n  7)
ter
ment p
Before
Treatment
After
Treatment p
9.9 0.0001 6.5  1.4 6.5  1.9* 0.81
6.3 0.0001 4.37  1.65 4.3  1.6* 0.45
2.6 0.0028 0.10  0.07 0.13  0.08* 0.06
0.14 0.41 0.04  0.03 0.06  0.04 0.20
0.53 0.0101 0.41  0.16* 0.56  0.31* 0.27
0.89 0.05 1.63  0.64 1.51  0.38 0.44
.010 0.13 0.103  0.11 0.126  .073* 0.41
0.3 0.0002 4.5  1.1 4.4  1.4* 0.40
0.2 0.0001 1.2  0.2 1.3  0.4 0.88
10.9 0.037 3.1  0.1 3.5  1.1* 0.41
7.0 0.039 3.3  1.1 2.7  1.0* 0.26
353 0.014 560  494 670  319 0.14
7.0 0.59 3.0  0.0 3.0  0.0 —
57.7 0.38 9.0  0.0 44.0  42.8 0.07
14.6 0.26 2.0  0.1 2.4  0.9 0.33
1,495 0.12 1,731  945 2,851  883 0.033
ny-stimulating factor; HDL  high-density lipoprotein; MCP-1  monocyte
rowth factor.
Changes
SF (n  7) Placebo (n  7)
After
Treatment p
Before
Treatment
After
Treatment p
2.2  0.7 0.0392 0.9  0.6 0.8  0.4* 0.16
0.5  0.3 0.14 1.8  2.8 0.5  0.6 0.30
1.1  1.0 0.0011 4.6  2.3 5.1  3.3* 0.33
6 (43) 0.04 9 (75) 12 (86) 0.78
.159  0.07 0.0281 0.166  0.06 0.166  0.04 0.98
.051 0.001  0.037 0.0351
3 (43) 0.15 5 (71) 6 (86) 0.77
.134  0.08 0.05 0.173  0.08 0.166  0.03 0.78
.037 0.007  0.047 0.11
3 (43) 0.15 4 (57) 6 (86) 0.55
.183  0.07 0.23 0.163  0.05 0.166  0.04 0.80
.067 0.003  0.034 0.20SF (
Af
Treat
1.4 
2.1 
4.7 
.08 
.18 
.37 
11 
3.0 
0.9 
8.0 
2.7 
68 
2.2 
5.3 
0.5 
49 Flow
M-C
0
2  0
0
3  0
0
1  0
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November 1, 2005:1636–42 Systemic GM-CSF and Collateralsow, and that this is related to enhanced TNF-alpha
roduction with monocytic TNF receptor-1 up-regulation.
he safety of the drug with regard to atherosclerotic plaque
upture in this study is questionable.
echanism of GM-CSF’s efficacy in arteriogenesis. The
herapeutic use of a substance for the promotion of monocytes
uch as GM-CSF has been evaluated in one experimental and
ne clinical study (2,7). Buschmann et al. (7) found that a
ontinuous infusion of GM-CSF into the stump of the acutely
ccluded femoral artery of rabbits enhanced the maximal blood
ow of the hindquarter five-fold. The mechanism of action in
hat study was found to be the prolonged survival of mono-
ytes. In the present study, the only independent factor
nfluencing CFI change following GM-CSF was TNF-alpha
long with an up-regulation of the corresponding receptor.
his is in keeping with the results of earlier experimental
tudies on the role of this cytokine in arteriogenesis (8). It has
lso been hypothesized that GM-CSF could unfold its effect
igure 3. Individual data of collateral flow index (CFI, vertical axis; black
horizontal axis) among patients of the GM-CSF (granulocyte-macrophage
lue lines connect the mean ( SD) CFI before and after treatment.
igure 4. Correlation between treatment-induced change in collateral flow
ndex (CFI, vertical axis) and the respective change in tumor necrosis
actor-alpha concentration (TNF-alpha, horizontal axis), i.e., the only
ndependent predictor among 11 factors (see text) of CFI. Black symbolsm
ndicate values obtained in stenotic, blue symbols in normal vessels,
espectively. *Value after treatment minus value before treatment.n arteriogenesis by releasing pluripotent stem cells from the
one marrow into the circulation, which would then be
ncorporated as endothelial cells into the growing collateral
rtery (7). Determination of CD34 progenitor cells in the
resent study does not support this hypothesis, because GM-
SF did not relevantly alter the count of these cells. Nor does
t undermine the possibility that progenitor cells play a role in
rteriogenesis, because the time when the blood was collected
or assessing CD34 cells may have been inadequate for
etecting their change. A specific group of progenitor cells, i.e.,
eripheral blood endothelial progenitor cells, has been found
ot to proliferate but to release pro-angiogenic growth factors
nd to be mainly derived from monocytes/macrophages (9).
imilarly, a recent study has documented that bone-marrow-
erived cells do not incorporate into the growing vasculature of
ice (10). This indicates that there may be no need taking the
detour” of bone marrow mobilization or even transplantation
o arrive at enhanced collateral vessels.
he role of GM-CSF in clinical arteriogenesis. Directly
romoting peripheral or also bone marrow-derived mono-
ytes by, for example, GM-CSF is a scientifically sound
oncept of collateral artery promotion acting via the pro-
uction of an entire “cocktail” of cytokines. The few
ontrolled clinical trials that have employed solitary angio-
enic growth factors have failed to extrapolate the promising
esults from animal studies into the therapeutic area of
uman patients (3,4). This failure may not only be related to
he selection of growth factors that induce capillary sprout-
ng, but also to the choice of study end points (SPECT
uring vessel patency, exercise time) that are inadequate for
elective assessment of collaterals (i.e., the parameter of
nterest hypothesized to be beneficially influenced by the
ubstance under investigation).
Aside from a simplification of the subcutaneous-only
tudy protocol, to find GM-CSF effective supports the
ypothesis of “homing” of monocytes, i.e., the concept that
hey attach locally to vascular endothelium subject to aug-
) obtained in stenotic as well as normal vessels before and after treatment
y-stimulating factor, left panel) and the placebo group (right panel). Thelines
colonented shear forces because of a pressure drop along a
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home” at vascular sites exposed to high shear forces for
ther reasons than a perfusion pressure gradient between
ollateral supplying and receiving artery, for example, at an
therosclerotic plaque obstructing the epicardial coronary
rtery.
M-CSF and atherogenesis/atherogenic plaque rupture.
onsidering in this context the role of monocytes in
therogenesis, it is conceivable that the use of GM-CSF
ay translate into the rupture of atherosclerotic plaques
longside the growth of collateral arteries. Theoretically, a
ro-atherogenic action of GM-CSF could be imagined via
ts MCP-1 elevating effect, which could be observed in the
resent study. Van Royen et al. (5) demonstrated in apoli-
oprotein E-deficient mice that local MCP-1 therapy in the
igated femoral artery augmented collateral artery formation
nd atherosclerotic plaque progression. In the present study,
wo patients in the GM-CSF group, but none in the
lacebo group, had had an acute coronary syndrome, very
ikely because of an atherosclerotic plaque rupture. Consid-
ring that “no-option” patients with extensive CAD are the
ost likely candidates for a therapy with GM-CSF, safety
f the drug in relation to acute coronary syndromes cannot
e guaranteed. This interpretation of the study results can
lso be extended to patients with subclinical CAD receiving
M-CSF for other indications.
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